Close Menu
Home › Cancer Genetics Q4 Revenues Up 32 Percent

Cancer Genetics Q4 Revenues Up 32 Percent

Mar 23, 2017

NEW YORK (GenomeWeb) – Cancer Genetics reported today that its fourth quarter revenues grew 32 percent year over year.

For the three months ended Dec. 31, 2016, the company reported revenues of $7.2 million up from $5.5 million in Q4 2015.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jun
13
Featured Webinar

Lowering RNA-seq Costs via Enzymatic rRNA Depletion with Custom, Species-specific Probes

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type. 

Jun
17
Featured Webinar

Personal and Clinical Utility of Polygenic Risk Scores: A Review of the Evidence

This webinar will provide an overview of polygenic risk scores, which aggregate dozens of genetic variants that have been linked to disease risk in genome-wide association studies (GWAS) into a single score.

Jun
25
Featured Webinar

Error-Corrected Sequencing to Detect Measurable Residual Disease in Post-Transplant MDS Cases

What's Popular?

In Cancer

  1. FDA Approves Qiagen's PIK3CA Test as Companion Test for Novartis Breast Cancer Drug

  2. Local Coverage Determinations Roundup: Natera, Guardant Health, Transplant Genomics, and More

  3. Beckman Coulter Life Sciences Recalls Hematology Analyzers Due to Risk of Inaccurate Results

  4. Guardant Health Prices $319.5M Public Stock Offering

  5. Dutch Dx Alliance Plans Early-Stage Cancer Tests on Photonics-Based Chip Platform

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.